SGLT2 inhibitors in heart failure: insights from plasma proteomics-Reference-Cited by-同舟云学术

SGLT2 inhibitors in heart failure: insights from plasma proteomics

Published:2022-11-07 Issue:48 Volume:43 Page:5003-5005
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Gutmann Clemens¹^ORCID,Zelniker Thomas A²^ORCID,Mayr Manuel¹²^ORCID

Affiliation:

1. School of Cardiovascular and Metabolic Medicine & Sciences, King’s College London British Heart Foundation Centre , 125 Coldharbour Lane, London SE5 9NU , UK

2. Division of Cardiology, Medical University of Vienna, Austria

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

https://academic.oup.com/eurheartj/article-pdf/43/48/5003/48306012/ehac624.pdf

Reference15 articles.

1. The rosiglitazone decision process at FDA and EMA. What should we learn?;Pouwels;Int J Risk Saf Med,2012

2. Dapagliflozin in patients with heart failure and reduced ejection fraction;McMurray;N Engl J Med,2019

3. Cardiovascular and renal outcomes with empagliflozin in heart failure;Packer;N Engl J Med,2020

4. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials;Zelniker;Lancet,2019

5. Empagliflozin in heart failure with a preserved ejection fraction;Anker;N Engl J Med,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium-glucose cotransporter type 2 inhibitors in the treatment of chronic heart failure: new evidence;Meditsinskiy sovet = Medical Council;2024-05-19

2. Proteomic Associations of Adverse Outcomes in Human Heart Failure;Journal of the American Heart Association;2024-03-05

3. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors for heart failure with mildly reduced or preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials;Frontiers in Cardiovascular Medicine;2023-10-12

4. Addressing the pandemic of heart failure: old and new therapeutic opportunities;European Heart Journal;2023-06-07

5. Focus on trials: dementia, lipids, thrombosis, and heart failure;European Heart Journal;2022-12-21